Berlin, Germany and Nevada, USA, October 27, 2016 - MagForce AG (Frankfurt, Entry Standard, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in four upcoming scientific and investor conferences in the fourth quarter 2016:
• 13th AIO Autumn Convention - Oncology in Internal Medicine Working Group (AIO) – Update Medical Oncology
Date: November 17-19, 2016
Location: Berlin, Germany
Booth: No. 24, level 1
• 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO)
Date: November 17-20, 2016
Location: Scottsdale, Arizona, USA
Presentation: “Inflammatory response after modified NanoTherm® and radiotherapy of recurrent glioblastoma”
Presenter: Team of Prof. Dr. med. Walter Stummer, Director of the Clinic for Neurosurgery, University Hospital Münster
Speaker: Dr. Dr. med. Oliver Grauer, Head of Neuro-Oncology Team, University Hospital Münster
Date of presentation: Friday, November 18, 2016; Poster session 19:00 MST
• German Equity Forum
Date: November 21-23, 2016
Location: Frankfurt, Germany
Presentation: Ben J. Lipps, CEO of MagForce AG, Monday, November 21, 2016, 14:00 CET Room: Oslo
• NOA Winter School 2016 – Neurological Working Group
Date: December 1-2, 2016
Location: Münster, Germany
Presentation: “Local Hyperthermia as an adjuvant for malignant glioblastoma – NanoTherm and NanoPaste”
Speaker: Dr. med. Johannes Wölfer, Deputy Director of the Neurosurgical Department, Clinic and Policlinic for Neurosurgery, University Hospital Münster
Date of presentation: Thursday, December 1, 2016, 15:00 CET
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group’s proprietary NanoTherm™ therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.
NanoTherm™, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm™, NanoPlan, and NanoActivator® are trademarks of MagForce AG in selected countries.
